About Apnimed
Apnimed is a publicly listed company based in Cambridge (United States) founded in 2017 by Lawrence G Miller. Small molecule therapeutics for obstructive sleep apnea are developed. Apnimed has raised $249.33 million across 9 funding rounds from investors including NexPoint, Alpha Wave Global and Sectoral Asset Management. Its chief executive, as recorded, is Lawrence G Miller. Its website apnimed.com draws about 29 thousand monthly visits. Apnimed offers products and services including AD109. Its focus areas include Life Sciences, Sleep Medicine, Drugs and Neurology. Its legal entity is Apnimed Inc. Its competitors include Somnus Therapeutics and Imbrium Therapeutics; 1 of its 2 listed competitors has raised funding.
Company details
Apnimed was founded in 2017 and is based in Cambridge, United States. Small molecule-based therapeutics are developed by the company within the biotechnology sector for treating obstructive sleep apnea. A combination therapy of atomoxetine and oxybutynin has been formulated to lessen the conditions severity. Neurological mechanisms controlling upper airway dilator muscles are addressed, resulting in enhanced respiration and oxygenation while sleeping. Operations focus on advancing these treatments through clinical development.
- Headquarters Cambridge, United States
- Founders Lawrence G Miller
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website apnimed.com
- Social LinkedIn X
- Legal Name Apnimed, Inc.
- Annual Revenue$38.47 M (USD)380.12as on Dec 31, 2025
- Net Profit-$128.19 M (USD)-15.17as on Dec 31, 2025
- EBITDA-$53.79 M (USD)52.9as on Dec 31, 2025
- Total Equity Funding$249.33M (USD)
in 9 rounds
- Latest Funding Round$50M (USD), Debt – Conventional
Apr 2026
- InvestorsNexPoint
& 6 more
Products & Services of Apnimed
Apnimed offers a comprehensive portfolio of products and services, including AD109.
Investigational treatment for improving oxygenation in obstructive sleep apnea.
Funding Insights of Apnimed
Apnimed has successfully raised a total of $249.33M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $50 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $249.33M
- Total Rounds 9
- Last Round Debt – Conventional — $50M
- First Round $25.58M
(Aug 2019)
- Investors Count 7
All 9 funding rounds of Apnimed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $50M | Debt – Conventional | – | – | – |
| Mar 2026 | $25M | Series C | – | – | – |
| Sep 2025 | $23M | Debt – Conventional | – | – | – |
| Apr 2025 | $16.5M | Series C | – | – | – |
| Dec 2022 | $79.75M | Series C | – | Alpha Wave Global | |
| Nov 2022 | $62.5M | Series C | – | Sectoral | |
| Mar 2021 | $25M | Series B | – | Morningside | |
| Apr 2020 | $15M | Series A | – | – | – |
| Aug 2019 | $25.58M | Series A | – | Morningside | – |
7 investors in total: 7 institutional.
Investors in Apnimed
Apnimed has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include NexPoint, Alpha Wave Global and Sectoral Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on growth-stage companies | alphawaveglobal.com | New York, United States | ||
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Venture capital firm focused on multiple sectors | taocap.com | Marlborough, United States | ||
Hedge, real estate, and climate tech investments are managed. | 1993 | nexpoint.com | Dallas, United States | |
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Manages diversified investment portfolios across various asset classes. | 1985 | columbiathreadneedleus.com | United States |
Investor details for Apnimed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Apnimed
19 people are tracked at Apnimed (16 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Lawrence G Miller | Founder & CEO | Leadership |
Andrew Wellman, MD, PhD | Co-Founder | Leadership |
John Cronin, MD | Senior Vice President - Clinical Development | Leadership |
Ramzi Benamar | Chief Financial Officer | Leadership |
Mandy Core | Senior Medical Director, Medical Affairs | Leadership |
Gina Marek CPA, MBA | Senior Vice President Finance | Leadership |
Harry Novotny | National Account Director | Leadership |
Graham Goodrich | Chief Commercial Officer (cco) | Leadership |
Jeff Krol | Vice President, Managed Markets & Access Strategy | Leadership |
Diego Rodriguez | VP Insights, Analytics, And Planning | Leadership |
Hsuan-Ming Yao | Director Of Clinical Pharmacology | Leadership |
Kate Schneider | Associate Director - Commercial | Leadership |
Bret Calder | Sr Director Trade Affairs | Leadership |
Sonnie Kang | Vice President, Commercial Strategy | Leadership |
Patrick Jensen | Head Of Field Medical | Leadership |
Tina Rhinehart | National Account Director | Leadership |
Bryan Corbett | Controller | Team |
Nancy Yarley | Sr Manager | Team |
Swetha Ravichandiran | Regulatory And Clinical Operations Intern | Team |
Complete people profiles for Apnimed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Apnimed
Apnimed is a publicly listed company on the NASDAQ with ticker symbol APMD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Jul 2026
- Listed onNASDAQ: APMD
- Listed entityApnimed, Inc.
- Exchange sectorHealth technology
- ISINUS03770Y1073
- Share price$17.83 (-4.29% on the day) · 2026-10-13
- Market capitalisation$742.3M
- Volume (last session)215,572
Financials of Apnimed
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $38.5M | -$128.2M | -$53.8M |
| 2024 | $8.0M | -$111.3M | -$114.2M |
| 2023 | -$80.2M | -$48.5M | |
| 2022 | $1.0M | -$26.2M | -$26.6M |
Detailed financial statements for Apnimed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Apnimed
4 dated milestones of Apnimed across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Apnimed is founded.
- Funding First funding round of $25.6M.
- Funding Latest funding round, Debt – Conventional, of $50.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Apnimed
Apnimed has 2 listed competitors in our database, 1 of them funded. They include Somnus Therapeutics and Imbrium Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somnusthera.com | 2007 | Bedminster, United States | $15M | Controlled-release sleep maintenance therapeutics are developed by the company. | ||
| imbriumthera.com | 2019 | Stamford, United States | Develops novel therapeutics for CNS, oncology, and non-opioid pain via partnerships and pipelines. |
Detailed competitors of Apnimed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Apnimed
The website of Apnimed (apnimed.com) receives about 29.1K visits a month.
- Monthly visits29.1K
▲ 76.5% vs previous month
Websites whose visitors overlap most with Apnimed. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sleephealth.org | sleephealth.org | 100% | #1,441,695 | – |
Top companies in Neurology
3 companies that operate in the same segment as Apnimed (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apnimed
Complete news archive for Apnimed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apnimed
Apnimed was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Apnimed is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Lawrence G Miller is the CEO of Apnimed, as recorded in our data. They have also founded this company.
Apnimed is a funded company, having raised a total of $249.33M across 9 funding rounds to date. The company's 1st funding round was a Series A of $25.58M, raised on Aug 2019.
Annual revenue of Apnimed is $38.47M as on Dec 31, 2025.
Apnimed was founded in 2017 and is based in Cambridge, United States. Small molecule-based therapeutics are developed by the company within the biotechnology sector for treating obstructive sleep apnea. A combination therapy of atomoxetine and oxybutynin has been formulated to lessen the conditions severity. Neurological mechanisms controlling upper airway dilator muscles are addressed, resulting in enhanced respiration and oxygenation while sleeping. Operations focus on advancing these treatments through clinical development.
Apnimed's top competitors include Somnus Therapeutics and Imbrium Therapeutics.
Apnimed offers AD109.
Yes, Apnimed is publicly traded on NASDAQ under the ticker symbol APMD.
Apnimed has 7 investors. Key investors include NexPoint, Alpha Wave Global, Sectoral Asset Management, Tao Capital Partners, and Columbia-Seligman Investments.
Apnimed operates through Apnimed Inc.